The board of directors of WuXi Biologics (Cayman) Inc. announced that Dr. Weichang Zhou ("Dr. Zhou") will retire on March 31, 2024. On that day, he will retire from his roles as Chief Technology Officer and President of Global Biologics Development and Operations of the Company. Following his retirement as senior management of the Company, Dr. Zhou will be re-designated as a non-executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer to continue to support the Company's development.

Dr. Zhou will remain as a member of the strategy committee of the Board. As an experienced expert in the field of biologics development and manufacturing, Dr. Zhou has been diligent and professional in his duties since he joined the Group in December 2012. He has made immense contributions to the Company's development.

The Board as well as the entire management level and staff would like to express their sincere gratitude to Dr. Zhou for his dedications during his tenure of office over the past 11 years. The Board would also like to announce that Dr. Sherry Gu ("Dr. Gu") has been appointed and will take over Dr. Zhou's position as Chief Technology Officer and Executive Vice President of Global Biologics Development Department of the Company upon Dr. Zhou's retirement. Dr. Gu, aged 53, joined the Company in 2017 as the Vice President of CMC (Chemistry, Manufacturing and Controls) Management for the West Coast of the United States, and expanded her responsibilities to include the East Coast of the United States in 2019 and Europe in 2021.

During such period, she led numerous early and late-stage CMC projects directly and achieved several project IND (Investigational New Drug), PPQ (Process Performance Qualification) and approval milestones, including from DNA to EUA (Emergency Use Authorization) approval of Sotrovimab through the VIR-GSK collaboration in the combat of the worldwide COVID-19 pandemic. Dr. Gu received her Ph.D. in Biochemical Engineering from Massachusetts Institute of Technology and has been working in the biopharmaceutical field for over 25 years, including 2 years at Bristol Myers Squibb and 18 years at Eli Lilly and Company prior to joining the Company.